Johan Löf, founder and CEO, RaySearch, says: “Further enhancing the capabilities of multi-modality treatments is key for RaySearch in the ambition to provide tools to create the best treatment plans for cancer patients. With RayStation 2024A we also continue with improvements within fast adaptive re-planning, which will be an important focus area during the coming years.”

Starting this December, SeekIn’s comprehensive range of cancer detection tests, namely OncoSeek, SeekInCare, SeekInCure and SeekInClarity will be distributed by Oncolnv in the following twelve countries: Belgium, Bulgaria, Costa Rica, Egypt, Ghana, Kenya, the Netherlands, Nigeria, Qatar, Singapore, Tanzania and UAE.

EMA assessed arpraziquantel under the EU-M4all procedure for high-priority medicines intended for use in countries outside the European Union. Merck KGaA, Darmstadt, Germany, is committed to contribute to the elimination of schistosomiasis as a public health problem by 2030.

Research shows no discernable differences in graft versus host disease, relapse free survival or overall survival for patients who had a Hematopoietic Cell Transplant (HCT) with an 8/8 or 7/8 Unrelated Donor (URD) for adult patients with malignancies.